Targeting binding function-3 site on the androgen receptor to treat Enzalutamide-resistant prostate cancer

被引：0
|
作者：
Munuganti, Ravi Shashi Nayana [1 ]
Hassona, Mohamed D. H. [1 ]
Leblanc, Eric [1 ]
Guns, Emma T. [1 ]
Rennie, Paul S. [1 ]
Cherkasov, Artem [1 ]
机构：
[1] Vancouver Prostate Ctr, Vancouver, BC, Canada
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-3654
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3654
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer
    Abudurexiti, Mierxiati
    Zhu, Wenkai
    Wang, Yuchen
    Wang, Jun
    Xu, Wenhao
    Huang, Yongqiang
    Zhu, Yao
    Shi, Guohai
    Zhang, Hailiang
    Zhu, Yiping
    Shen, Yijun
    Dai, Bo
    Wan, Fangning
    Lin, Guowen
    Ye, Dingwei
    PROSTATE, 2020, 80 (12): : 950 - 961
  • [32] Neuropilin-2 promotes enzalutamide-resistant neuroendocrine prostate cancer
    Wang, Jing
    Li, Jingjing
    Wu, Boyang
    Yin, Lijuan
    CANCER RESEARCH, 2020, 80 (16)
  • [33] Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation
    Lallous, Nada
    Leblanc, Eric
    Munuganti, Ravi S. N.
    Hassona, Mohamed D. H.
    Al Nakouzi, Nader
    Awrey, Shannon
    Morin, Helene
    Roshan-Moniri, Mani
    Singh, Kriti
    Lawn, Sam
    Yamazaki, Takeshi
    Adomat, Hans H.
    Andre, Christophe
    Daugaard, Mads
    Young, Robert N.
    Guns, Emma S. Tomlinson
    Rennie, Paul S.
    Cherkasov, Artem
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (12) : 2936 - 2945
  • [34] Prostate cancer RIPTAC™ therapeutics demonstrate activity in preclinical models of Enzalutamide-resistant prostate cancer
    Yu, Xinheng
    Eastman, Kyle J.
    Raina, Kanak
    Jones, Kelli M.
    Forbes, Chris D.
    Hundt, Abigail
    Garcia, Marco
    Stronk, Rebecca
    Howard, Katia
    McGovern, Andrew
    Chenard, Rebekka
    Denny, Allison
    Forgione, Mia
    Bassoli, Kyle
    Garvin, Ethan
    Mousseau, James J.
    Li, Hao
    King, Madeline P.
    Bhardwaj, Amit
    Kayser-Bricker, Katherine J.
    Crews, Craig M.
    CANCER RESEARCH, 2023, 83 (07)
  • [35] Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer
    Schalken, Jack
    Fitzpatrick, John M.
    BJU INTERNATIONAL, 2016, 117 (02) : 215 - 225
  • [36] A Pyrrole-Imidazole Polyamide Is Active against Enzalutamide-Resistant Prostate Cancer
    Kurmis, Alexis A.
    Yang, Fei
    Welch, Timothy R.
    Nickols, Nicholas G.
    Dervan, Peter B.
    CANCER RESEARCH, 2017, 77 (09) : 2207 - 2212
  • [37] MCT INHIBITION AS A POTENTIAL THERAPEUTIC STRATEGY TO TARGET ENZALUTAMIDE-RESISTANT PROSTATE CANCER
    Bhattacharjee, Sayani
    Doan, Jonathan P.
    Pletcher, Jerred P.
    Wynn, Rebecca
    Petros, Firas
    Sindhwani, Puneet
    Nadiminty, Nagalakshmi
    JOURNAL OF UROLOGY, 2020, 203 : E767 - E767
  • [38] Aberrant Super-Enhancer Landscape in Enzalutamide-Resistant Prostate Cancer Cells
    Cai, Chao
    Liu, Qinwei
    Shan, Haoran
    Zhong, Chuanfan
    Chen, Guidong
    Cai, Zhouda
    Zheng, Yu
    Lu, Jianming
    Tang, Jiaojiao
    Lin, Zhuoyuan
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2024, 28 (06) : 243 - 256
  • [39] MCT inhibition as a therapeutic strategy to target Enzalutamide-resistant prostate cancer.
    Bhattacharjee, Sayani
    Doan, Jonathan
    Wynn, Rebecca
    Nadiminty, Nagalakshmi
    CANCER RESEARCH, 2021, 81 (13)
  • [40] Aberrant tumor metabolism enables GR takeover in enzalutamide-resistant prostate cancer
    Li, Jianneng
    CANCER RESEARCH, 2017, 77
12345